Drugs / ODM-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01766258 | May 2011 → Aug 2012 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-03-21 | Orion Corporation, Orion Pharma | Results Orion Corporation presented promising Phase II data for new Parkinson's disease drug at AAN Annual Meeting orionpharma.com ↗
Both ODM-101/65 mg and ODM-101/105 mg reduced daily OFF-time from baseline more than Stalevo. |
| 2012-10-23 | Orion Corporation, Orion Pharma | Results Orion receives positive Phase II study results of a new levodopa product for Parkinson's disease orionpharma.com ↗
The key results indicate that ODM-101 was more efficacious than the reference product Stalevo® in the treatment of advanced Parkinson's disease patients. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-03-21 | Orion Corporation, Orion Pharma | Orion Corporation presented promising Phase II data for new Parkinson's disease drug at AAN Annual Meeting orionpharma.com ↗ |
| 2012-10-23 | Orion Corporation, Orion Pharma | Orion receives positive Phase II study results of a new levodopa product for Parkinson's disease orionpharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01766258 ↗ |